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We have previously demonstrated that determination of the rate of change of creatine kinase (CK) and creatine kinase MB (CK-MB) activity or concentration (slope measurement) in serial samples obtained within 12 h of admission from patients presenting with acute (less than 12 h duration) chest pain allows rapid and highly efficient diagnosis. I , 2 The measurement which produced the greatest discriminant between infarct and non-infarct groups in our preliminary study was CK-MB concentration (mass) measurements. CK-MB concentration measurements can now be performed rapidly in the emergency laboratory. We therefore further examined this method to determine if reliable diagnosis can be achieved by slope measurements using a shorter than 12 h time series.
Methods
The study was carried out on all patients admitted to the coronary care unit with cardiac symptoms Correspondence: Dr P a Collinson. of less than 12 h duration. All were assessed by clinical examination and serial electrocardiography. The cardiac enzyme protocol in use in the laboratory [measurement of aspartate transaminase (AST) and hydroxybutyrate dehydrogenase (HBD) for three consecutive days after admission] was also followed.
On patients in whom myocardial infarction had been excluded further investigation was carried out by stress electrocardiography or persantin thallium scintigraphy. Coronary angiography was performed on patients with positive stress electrocardiograms or persantin thallium scans, or when equivocal investigations were accompanied by a strong clinical suspicion of ischaemic heart disease. When ischaemic heart disease was excluded an alternative diagnosis was sought.
On the basis of clinical records, electrocardiograms, cardiac enzymes and follow up studies a final diagnostic classification was produced. Acute myocardial infarction (AMI) was judged to have occurred in patients with a history of chest pain accompanied by the development of Q waves, chest pain and sudden death with post mortem evidence of recent myocardial infarction or ischaemic ECG changes and sudden death within 72 h of admission. S-T and T wave changes were taken to indicate infarction if there were typical changes in cardiac enzymes or evidence from cardiac imaging. Persistent residual S-T depression or T wave changes without changes in cardiac enzymes were classified as 'ischaemia ?infarction'. Patients without persistent ECG changes or enzyme changes were classified as 'non-infarct'. Followup studies confirmed or excluded ischaemic heart disease as a cause for cardiac symptoms in these patients. Information from changes in either CK, CK-MB activity or CK-MB concentration in the serial samples was not used in this classification.
Seventy-three patients presented with symptoms of less than 12 h duration, with a median of 3·92 h from onset to the first blood sample. There were 55 men and 18 women, age range 26 to 82 years, median 62 years. Using the criteria defined above, 40 patients were considered to have sustained acute myocardial infarction, three to have had 'ischaemia ?infarction', 22 to have had ischaemic heart disease without acute infarction and eight to have had non-ischaemic chest pain. In the acute myocardial infarction group, 20 received thrombolytic therapy with acyl plasminogen streptokinase activated complex (APSAC, Eminase), seven with streptokinase and 13 received no thrombolytic therapy. Median time from chest pain to first sample was 2· 95 h (range 0'75 to 6, Upper Quartile 4'03, Lower Quartile 2 '13) in the thrombolysed group and 5' 12 h (range 1 to 11· 17, Upper Quartile 6· 69, Lower Quartile 2,75) in the unthrombolysed group.
Blood samples were obtained from these patients on admission and 2, 4 and 8 h later. Sera were separated and analysed for CK and CK-MB activity or stored frozen at -20°C until analysed for CK-MB concentration.
AST and HBD were measured at 37°C by optimized methods on a PERSPECTIVE analyser (American Monitor, Burgess Hill, UK) by the manufacturer's recommended methods. The manufacturer's reagents were used for AST and commercially supplied reagents used for HBD (Merckotest HBDH, BDH Diagnostics, Poole, UK).
Total CK and CK-MB by immunoinhibition were measured at 30°C by optimized methods, both using commercially supplied reagents (CK NAC opt., CK-MB NAC opt., Boehringer Mannheim UK, Lewes, UK). All determinations were made using a centrifugal analyser (Encore, Baker Instruments, Windsor, UK).
CK-MB concentration was determined using the Hybritech Tandem-E CKMB assay system (Hybritech, Nottingham, UK) as recommended by the manufacturer. This technique uses monoclonal antibodies to the Band M subunits in a two-site sandwich assay specific for CK-MB protein. The detection limit for this method is 2 ",giL. All patients with CK-MB values at or below the detection limit were recorded as 2 ",giL for the purpose of data analysis. CK-MB concentrations greater than 75 ",giL were redetermined after dilution.
CK, CK-MB activity and CK-MB concentration slope was calculated, as previously described, I from values obtained from the sequential serum samples.
Receiver operator characteristic (ROC) curves were generated for all the data using both sample times taken from admission and times corrected for the onset of chest pain with values grouped into 4 h intervals. Sensitivity and specificity were calculated using cut-offs selected from the point of inflection of the ROC curves showing the closest approximation to the idealized ROC function. Classification into infarct and noninfarct categories by slope determination was performed for the 0-8 h slope using the discriminants (CK and CK-MB activity [log U/Llh] , 0'015: CK-MB concentration [log ",g/L/h] , O·02) determined during our previous studies of 0-12 h slopes.' For the 0-4 h slopes, discriminants were determined from the ROC curves. To investigate the effects of thrombolytic therapy, analysis was performed including and excluding AMI patients who had received thrombolytic therapy.
RESULTS
Cut-offs selected from the ROC curves were, CK-MB concentration 10 ",giL, CK activity 120 U/L, CK-MB activity 12 U/L. CK and CK-MB activity and concentration slope (4 h) 0'02. Of the individual tests the CK-MB concentration shows the best performance, with maximal sensitivity (100070) and specificity (100070) 8 h from admission or 12-16 h from onset of chest pain (Figs 1 and 2) . Excluding thrombolysed patients reduces sensitivity for all the markers except the CK-MB concentration in the uncorrected results (Figs 3 and 4) .
The CK-MB concentration slope had a sensitivity of 100070 for 0-4 and 0-8 h with DISCUSSION efficient than CK at 4 h from admission but less efficient 8 h from admission.
CK-MB mass concentration shows the best overall performance of the markers compared for the diagnosis of acute myocardial infarction. The quoted upper reference limit supplied by the manufacturer shows, in our hands, good separation between groups but optimal separation is seen at a value of 10 /Lg/L. Single measurement has a diagnostic sensitivity of 97' 5010 at 4 h from admission and is 100010 at 8 h from admission. Exclusion of thrombolysed patients further improves the sensitivity, probably due to the greater median time from presentation to time of sampling. Classification using the CK-MB concentration increment shows high sensitivity (100010) but low specificity. This reflects the method of calculation of the CK-MB slope which will give disproportionate weight to small changes in the absolute CK-MB values because assay imprecision is high at low CK-MB concentration values.
The CK slope over 0-8 h shows a higher sensitivity with thrombolysed patients excluded. This is due to the alteration in the kinetics of CK following thrombolysis and is due to one patient in the thrombolysed group with peak CK values at 2 and 4 h from admission. When thrombolysed patients are excluded the sensitivity becomes 100010. The specificity of the CK slope may be increased, as suggested by Rutty! by stipulating that at least one sample exceeds the upper reference limit. Slope determination may be expressed more simply as a percentage change, or ratio between samples. At a slope (log CK activity/h) of 0'02 there will be a mean change of 4·7010 over 1 h or 9'6010 over 2 h, 20·2010 over 4h, 44'5010 over 8h and 73'8010 over 12h. Determination of slope or simple increment is affected only by within-batch imprecision.
When accurately timed, a single measurement of CK-MB by a specific technique is the best single enzyme procedure for confirmation or exclusion of AMI. Other workers have shown this using electrophoresis for CK isoenzyme separation." Sample timing is critical and previous clinical experience has shown single measurements are unreliable! and that there may be uncertainties in timing chest pain." This suggests that serial sampling should always be performed. (Table 1) . CK-MB concentration measurement proved the most efficient strategy, as a single value or when combined with a slope. CK-MB activity was more CK and CK-MB determinations on and soon after admission can be used as a guide to the administration of thrombolytic therapy. Our data show that an admission CK-MB concentration value of 10 ",giL or greater will have a sensitivity for diagnosis of AMI of less than 500/0 but high specificity. At 4 h sensitivity will be 100%. Slope CK also offers 100% sensitivity at 4 h. Other workers have stated that stat determinations of CK-MB on admission do not have a role in the diagnosis of AMI. 7 A CK -MB of less than 10 ",giL on admission is unhelpful and should not exclude thrombolysis on ECG criteria. However, we would suggest that an admission CK-MB of above 10 ",giL, even with a non-diagnostic ECG, suggests infarction and could be an indication for thrombolytic therapy. If CK and CK-MB mass are not diagnostic on admission they should be repeated, as should the ECG. A rise in CK by greater than 20% andlor an increase in CK-MB mass to greater than 10 ",giL over the subsequent 4 h are indications for thrombolytic therapy. Similarly, a change in ECG is an indication for thrombolytic therapy.
In conclusion, CK-MB concentration measurements offer the best single analytical technique for the diagnosis of myocardial infarction in patients presenting with 12 h or less of chest pain, when performed as part of a time series. Cost and convenience may be maximized by prescreening such sample series by determination of CK slope and measuring MB concentration only on patients showing a diagnostic rise in CK. This combination had a 100% sensitivity and specificity 4 h from admission, When the diagnosis is uncertain this strategy could be used to decide if thrombolytic therapy is to be administered.
